

Stian Knappskog

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4384331/publications.pdf>

Version: 2024-02-01

97
papers

14,623
citations

147801

31
h-index

46799

89
g-index

105
all docs

105
docs citations

105
times ranked

28749
citing authors

#	ARTICLE	IF	CITATIONS
1	The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. <i>Endocrine-Related Cancer</i> , 2022, 29, 1-14.	3.1	62
2	C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer. <i>Nature Communications</i> , 2022, 13, 69.	12.8	16
3	Abstract P3-09-18: The association between genomic alterations and body mass index in patients with early breast cancer. <i>Cancer Research</i> , 2022, 82, P3-09-18-P3-09-18.	0.9	0
4	DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival. <i>Breast Cancer Research</i> , 2022, 24, .	5.0	11
5	Constitutional <i>BRCA1</i> methylation and risk of incident triple-negative breast cancer and high-grade serous ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10509-10509.	1.6	1
6	Impact of <i>MDM2</i> promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer. <i>Biomarkers</i> , 2021, 26, 302-308.	1.9	4
7	Polymorphisms in the TP53-MDM2-MDM4-axis in patients with rheumatoid arthritis. <i>Gene</i> , 2021, 793, 145747.	2.2	7
8	<i>ramr</i> : an R/Bioconductor package for detection of rare aberrantly methylated regions. <i>Bioinformatics</i> , 2021, 38, 133-140.	4.1	2
9	Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer. <i>Scientific Reports</i> , 2021, 11, 23463.	3.3	5
10	Assessment of tumor suppressor promoter methylation in healthy individuals. <i>Clinical Epigenetics</i> , 2020, 12, 131.	4.1	11
11	Golgi-Localized PAQR4 Mediates Antiapoptotic Ceramidase Activity in Breast Cancer. <i>Cancer Research</i> , 2020, 80, 2163-2174.	0.9	8
12	The novel microRNAs hsa-miR-nov7 and hsa-miR-nov3 are over-expressed in locally advanced breast cancer. <i>PLoS ONE</i> , 2020, 15, e0225357.	2.5	3
13	Title is missing!. , 2020, 15, e0225357.		0
14	Title is missing!. , 2020, 15, e0225357.		0
15	Title is missing!. , 2020, 15, e0225357.		0
16	Title is missing!. , 2020, 15, e0225357.		0
17	Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4235.	4.1	32
18	The circular RNome of primary breast cancer. <i>Genome Research</i> , 2019, 29, 356-366.	5.5	85

#	ARTICLE	IF	CITATIONS
19	Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC. <i>Cancer & Metabolism</i> , 2019, 7, 6.	5.0	51
20	Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers. <i>Scientific Reports</i> , 2019, 9, 5244.	3.3	19
21	ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab. <i>Scientific Reports</i> , 2019, 9, 17471.	3.3	26
22	Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma. <i>BMC Cancer</i> , 2019, 19, 11.	2.6	18
23	Constitutional Mosaic Epimutations – a hidden cause of cancer?. <i>Cell Stress</i> , 2019, 3, 118-135.	3.2	22
24	APOBEC3A/B deletion polymorphism and cancer risk. <i>Carcinogenesis</i> , 2018, 39, 118-124.	2.8	39
25	Introducing nano-scale quantitative polymerase chain reaction. <i>Biochemical and Biophysical Research Communications</i> , 2018, 506, 923-926.	2.1	5
26	BRCA1 methylation in newborns: genetic disposition, maternal transfer, environmental influence, or by chance only?. <i>Clinical Epigenetics</i> , 2018, 10, 128.	4.1	5
27	White Blood Cell <i>BRCA1</i> Promoter Methylation Status and Ovarian Cancer Risk. <i>Annals of Internal Medicine</i> , 2018, 168, 326.	3.9	37
28	High expression of the p53 isoform $\hat{1}^3$ is associated with reduced progression-free survival in uterine serous carcinoma. <i>BMC Cancer</i> , 2018, 18, 684.	2.6	15
29	Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 165, 228-235.	2.5	6
30	High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 177-190.	2.5	16
31	Effects of concomitant inactivation of p53 and pRb on response to doxorubicin treatment in breast cancer cell lines. <i>Cell Death Discovery</i> , 2017, 3, 17026.	4.7	20
32	MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk. <i>BMC Cancer</i> , 2017, 17, 97.	2.6	14
33	Tumor cells interact with red blood cells via galectin-4 - a short report. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 401-409.	4.4	11
34	Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. <i>Nature</i> , 2017, 543, 714-718.	27.8	229
35	The Functional Roles of the MDM2 Splice Variants P2-MDM2-10 and MDM2- $\hat{1}^5$ in Breast Cancer Cells. <i>Translational Oncology</i> , 2017, 10, 806-817.	3.7	3
36	Genomic Evolution of Breast Cancer Metastasis and Relapse. <i>Cancer Cell</i> , 2017, 32, 169-184.e7.	16.8	534

#	ARTICLE	IF	CITATIONS
37	Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells. <i>BMC Cell Biology</i> , 2017, 18, 17.	3.0	11
38	Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines. <i>Oncotarget</i> , 2017, 8, 41227-41241.	1.8	16
39	MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer. <i>Scientific Reports</i> , 2016, 6, 33153.	3.3	8
40	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. <i>Nature</i> , 2016, 534, 47-54.	27.8	1,760
41	Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. <i>International Journal of Cancer</i> , 2016, 139, 647-656.	5.1	79
42	Prevalence of the CHEK2 R95* germline mutation. <i>Hereditary Cancer in Clinical Practice</i> , 2016, 14, 19.	1.5	6
43	Promoter SNPs rs116896264 and rs73933062 form a distinct haplotype and are associated with galectin-4 overexpression in colorectal cancer. <i>Mutagenesis</i> , 2016, 31, 401-408.	2.6	3
44	EGFRVIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation. <i>Neuro-Oncology</i> , 2016, 18, 1644-1655.	1.2	78
45	The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian but not endometrial cancer. <i>Tumor Biology</i> , 2016, 37, 10697-10702.	1.8	20
46	Intra-individual genetic heterogeneity among liver metastases in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 555-555.	1.6	1
47	Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection. <i>PLoS Genetics</i> , 2016, 12, e1006225.	3.5	64
48	Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate. <i>Oncotarget</i> , 2016, 7, 28637-28646.	1.8	22
49	MDM4 SNP34091 (rs4245739) and its effect on breast, colon, lung, and prostate cancer risk. <i>Cancer Medicine</i> , 2015, 4, 1901-1907.	2.8	33
50	Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0134351.	2.5	8
51	Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon. <i>International Journal of Cancer</i> , 2015, 137, 96-103.	5.1	27
52	Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens. <i>Tumor Biology</i> , 2015, 36, 1003-1013.	1.8	37
53	Subclonal diversification of primary breast cancer revealed by multiregion sequencing. <i>Nature Medicine</i> , 2015, 21, 751-759.	30.7	711
54	Concomitant inactivation of the p53 and pRB functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo. <i>Molecular Oncology</i> , 2015, 9, 1553-1564.	4.6	23

#	ARTICLE	IF	CITATIONS
55	Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. <i>Genome Research</i> , 2015, 25, 814-824.	5.5	69
56	<i>p53</i> status predicts long-term survival in locally advanced breast cancer after primary chemotherapy. <i>Acta Oncologica</i> , 2014, 53, 1347-1355.	1.8	14
57	Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. <i>Science</i> , 2014, 345, 1251343.	12.6	348
58	MDM2 SNP309 and risk of endometrial cancer. <i>Tumor Biology</i> , 2014, 35, 7285-7286.	1.8	0
59	Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. <i>Nature Genetics</i> , 2014, 46, 487-491.	21.4	254
60	MDM2 SNP309 and risk of cervical cancer. <i>Tumor Biology</i> , 2014, 35, 6185-6186.	1.8	3
61	Effects of SNP variants in the <i>17β-HSD2</i> and <i>17β-HSD7</i> genes and <i>17β-HSD7</i> copy number on gene transcript and estradiol levels in breast cancer tissue. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 143, 192-198.	2.5	8
62	Genomic heterogeneity in primary breast cancer: Clinical implications. <i>Journal of Clinical Oncology</i> , 2014, 32, 11004-11004.	1.6	1
63	Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649). <i>Oncotarget</i> , 2014, 5, 8223-8234.	1.8	22
64	Outcome after surgery for primary hyperaldosteronism may depend on <i>KCNJ5</i> tumor mutation status: a population-based study from Western Norway. <i>Langenbeck's Archives of Surgery</i> , 2013, 398, 869-874.	1.9	34
65	Signatures of mutational processes in human cancer. <i>Nature</i> , 2013, 500, 415-421.	27.8	8,060
66	Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 867-876.	3.3	16
67	Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2013, 1830, 2790-2797.	2.4	8
68	Inverse Regulation of EGFR/HER1 and HER2-4 in Normal and Malignant Human Breast Tissue. <i>PLoS ONE</i> , 2013, 8, e74618.	2.5	16
69	Letter to the editor MDM2 SNP309 and risk of endometrial cancer. <i>Polish Journal of Pathology</i> , 2013, 1, 69-69.	0.3	2
70	CXXC5 (Retinoid-Inducible Nuclear Factor, RINF) is a Potential Therapeutic Target in High-Risk Human Acute Myeloid Leukemia. <i>Oncotarget</i> , 2013, 4, 1438-1448.	1.8	20
71	Elevated levels of the steroidogenic factor 1 are associated with over-expression of CYP19 in an oestrogen-producing testicular Leydig cell tumour. <i>European Journal of Endocrinology</i> , 2012, 166, 941-949.	3.7	13
72	Re: <i>p53</i> promoter SNP309 polymorphism and prostate cancer risk: a meta-analysis. <i>International Journal of Urology</i> , 2012, 19, 966-966.	1.0	0

#	ARTICLE	IF	CITATIONS
73	Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. <i>Breast Cancer Research</i> , 2012, 14, R47.	5.0	58
74	Chemosensitivity and p53; new tricks by an old dog. <i>Breast Cancer Research</i> , 2012, 14, 325.	5.0	4
75	Effect of CYP19 rs6493497 and rs7176005 haplotype status on in vivo aromatase transcription, plasma and tissue estrogen levels in postmenopausal women. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2012, 128, 69-75.	2.5	15
76	SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer. <i>European Journal of Cancer</i> , 2012, 48, 1988-1996.	2.8	43
77	Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers. <i>BMC Cancer</i> , 2012, 12, 454.	2.6	9
78	P53 and its molecular basis to chemoresistance in breast cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S23-S30.	3.4	57
79	MDM2 Promoter SNP344T>A (rs1196333) Status Does Not Affect Cancer Risk. <i>PLoS ONE</i> , 2012, 7, e36263.	2.5	12
80	The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians. <i>Cancer Cell</i> , 2011, 19, 273-282.	16.8	104
81	Alterations of the retinoblastoma gene in metastatic breast cancer. <i>Clinical and Experimental Metastasis</i> , 2011, 28, 319-326.	3.3	13
82	Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. <i>Cancer</i> , 2011, 117, 4617-4622.	4.1	233
83	Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk. <i>Transcription</i> , 2011, 2, 207-210.	3.1	34
84	Exploring Breast Cancer Estrogen Disposition: The Basis for Endocrine Manipulation. <i>Clinical Cancer Research</i> , 2011, 17, 4948-4958.	7.0	58
85	Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel. <i>PLoS ONE</i> , 2011, 6, e19249.	2.5	65
86	MDM2promoter SNP285 and SNP309; phylogeny and impact on cancer risk. <i>Oncotarget</i> , 2011, 2, 251-258.	1.8	39
87	Gene Expression Profiling-Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome. <i>Clinical Cancer Research</i> , 2010, 16, 3356-3367.	7.0	235
88	Spontaneous Malignant Transformation of Human Mesenchymal Stem Cells Reflects Cross-Contamination: Putting the Research Field on Track – Letter. <i>Cancer Research</i> , 2010, 70, 6393-6396.	0.9	278
89	Alterations in the p53 Pathway and p16INK4a Expression Predict Overall Survival in Metastatic Melanoma Patients Treated with Dacarbazine. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2514-2516.	0.7	10
90	Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers. <i>Molecular Cancer</i> , 2010, 9, 173.	19.2	29

#	ARTICLE	IF	CITATIONS
91	CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer. PLoS ONE, 2008, 3, e3062.	2.5	74
92	The level of synthesis and secretion of Gaussia princeps luciferase in transfected CHO cells is heavily dependent on the choice of signal peptide. Journal of Biotechnology, 2007, 128, 705-715.	3.8	84
93	NEW DOCTORIAL CANCER RESEARCH:Germline Genetic Alterations Affecting CDKN2A, MDM2, and CDKN1A in Melanoma and Breast Cancer Patients. Critical Reviews in Oncogenesis, 2007, 13, 261-263.	0.4	1
94	P21/WAF1 mutation and drug resistance to paclitaxel in locally advanced breast cancer. International Journal of Cancer, 2007, 120, 2749-2749.	5.1	1
95	Mutations and polymorphisms of thep21B transcript in breast cancer. International Journal of Cancer, 2007, 121, 908-910.	5.1	16
96	A novel type of deletion in theCDKN2A gene identified in a melanoma-prone family. Genes Chromosomes and Cancer, 2006, 45, 1155-1163.	2.8	22
97	The Novel p21 Polymorphism p21G251A Is Associated with Locally Advanced Breast Cancer. Clinical Cancer Research, 2006, 12, 6000-6004.	7.0	15